NCT07049770

Eczeva Supplementation and Skin Health

Completed NA Last updated 3 July 2025

What this trial tests

NA trial testing Eczeva supplementation in Skin in 50 participants. Completed in 31 May 2025.

Timeline

1 January 2025

Primary endpoint
28 February 2025

31 May 2025

Quick facts

Lead sponsor	Zest Healthtech PLT
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 January 2025
Primary completion	28 February 2025
Estimated completion	31 May 2025
Sites	1 location across Malaysia

Drugs / interventions tested

• Eczeva supplementation

Conditions studied

• Skin — all drugs for Skin →
• Eczema — all drugs for Eczema →

Sponsor

Zest Healthtech PLT

Who can join

18 and older, any sex, with Skin or Eczema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by inflamed, itchy, and often dry skin. It commonly affects individuals of all ages, although it frequently begins during childhood. The causes of eczema are multifactorial, including genetic, immune, and environmental factors. Genetic mutations, such as those in the FLG gene responsible for producing filaggrin, a protein vital to skin barrier function, play a significant role (1). Immune system dysregulation, particularly an overactive response to environmental allergens, also contributes to eczema (2). Environmental triggers are diverse and include irritants like soaps, detergents, and disinfectants, as well as allergens such as pollen, pet dander, dust mites, mold, and certain foods (3-8). Climatic conditions, such as cold or dry air, and high humidity, can exacerbate symptoms, as can exposure to air pollution and chlorinated water in swimming pools (3-8). Specific skincare products containing allergens or irritants may worsen the condition. Other factors influencing eczema include infections (bacterial, viral, or fungal) (9), dietary triggers like dairy, nuts, eggs, and soy (10), and clothing choices, with materials like wool and synthetics or tight-fitting clothes aggravating symptoms through skin irritation and friction (11, 12).

Individuals with certain habits or characteristics are at a higher risk of developing eczema. A family history of eczema, asthma, or hay fever significantly increases the likelihood of the condition, as it suggests a genetic predisposition (13). Emotional stress and anxiety are known to trigger or worsen eczema symptoms (14), as are hormonal changes during pregnancy or menstruation, which can cause flare-ups (15). People who sweat excessively may experience irritation and aggravation of eczema, as the moisture can exacerbate inflammation (16). Smoking or exposure to cigarette smoke is another contributing factor, known to both trigger and worsen eczema (17). Those working in professions with frequent exposure to irritants or allergens, such as healthcare or cleaning, are at higher risk due to contact with harsh chemicals (18). Additionally, excessive hand washing can strip the skin of its natural moisture, leading to irritation and exacerbating eczema symptoms (18).

The main active ingredient in Eczeva is Melicope ptelefolia. Melicope ptelefolia, commonly known as Tenggek Burung, has been used for centuries in traditional herbal medicine to treat various skin conditions, including wounds, itches, and skin diseases (19). The plant is known for its high content of bioactive compounds, particularly 2,4,6-trihydroxy-3-geranyl acetophenone (tHGA) and 2,4,6-trihydroxy-3-prenyl acetophenone (tHPA). Among these, tHGA has shown significant potential due to its inhibitory effects on lipoxygenase (LOX) activity, suggesting its anti-inflammatory properties that may help in treating conditions like eczema (20). An in vitro study demonstrated that tHGA reduced inflammatory markers and enhanced the integrity of the skin barrier, both of which are crucial for managing inflammation-related conditions like eczema (21). Further research also indicated that tHGA could improve epithelial barrier function and reduce cell permeability in inflamed tissues, a key factor in treating eczema, which is characterized by an impaired skin barrier function (22). These findings highlight the therapeutic potential of Melicope ptelefolia in managing eczema through its anti-inflammatory and barrier-strengthening effects.

Research on the efficacy of Melicope ptelefolia supplements in improving skin health in human is remain largely unexplored. This study aims to determine the mechanism and effects of Eczeva supplements on improving the skin health among users.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.